

## Expert Workshop: Facilitating Antibacterial Drug Development The Brookings Institution • Washington, DC Wednesday, May 9, 2012

# **Participant List**

## **Meghna Alimchandani** (teleconference) Clinical Fellow, National Cancer Institute

## **Daniel Benjamin**

Professor of Pediatrics and Faculty Associate Director, Duke Clinical Research Institute, Duke University School of Medicine

## **Robert Bonomo**

Professor, Case Western Reserve University and Service Chief, Medical Service, Louis Stokes Cleveland VA Medical Center

## **Helen Boucher**

Director, Infectious Diseases Fellowship Program, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Associate Professor of Medicine, Tufts University School of Medicine

# **Robert Califf**

Vice Chancellor for Clinical and Translational Research, Director of the Duke Translational Medicine Institute, Duke University Medical Center

### Marco Cavaleri (teleconference)

Head of Anti-Infectives and Vaccines, European Medicines Agency

# Mantej (Nimi) Chhina

Consumer Safety Officer, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

# Sally Cluchey

Senior Research Associate, Engelberg Center for Health Care Reform, The Brookings Institution

# **Deborah Collyar**

President, Patient Advocates In Research

# Allan Coukell

Deputy Director, Medical Safety Programs, The Pew Charitable Trusts

# Edward Cox

Director, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

## **Gregory Daniel**

Managing Director and Fellow, Engelberg Center for Health Care Reform, The Brookings Institution

## **Robert Danner**

Senior Investigator and Head, Infectious Diseases Section, Critical Care Medicine Department, National Institutes of Health

### George Drusano

Professor of Medicine and Director, Institute for Therapeutic Innovation, University of Florida College of Medicine

### **Mike Dudley**

Senior Vice President, Research & Development and Chief Scientific Officer, Rempex Pharmaceuticals, Inc.

### **Michael Dunne**

Chief Medical Officer, Durata Therapeutics

### **Barry Eisenstein**

Senior Vice President of Scientific Affairs, Cubist Pharmaceuticals and Clinical Professor of Medicine, Harvard Medical School

# Scott Emerson

Professor of Biostatistics, University of Washington

### John Farley

Deputy Director, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

## **Thomas Fleming**

Professor, Department of Biostatistics, University of Washington School of Public Health

# **David Friedland**

Vice President, Clinical Sciences, Cerexa, Inc.

## Mark Goldberger

Divisional Vice President, Regulatory Policy and Intelligence, Abbott Pharmaceuticals

#### **Cheryl Grandinetti**

Health Science Policy Analyst, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

### Joseph Griffin (teleconference)

Associate Director for Policy Development, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food & Drug Administration

#### **Robert Guidos**

Vice President, Public Policy & Government Relations, Infectious Diseases Society of America

### Mohammad Huque (teleconference)

Director, Division of Biometrics IV, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food & Drug Administration

### Audrey Jackson

Senior Program Officer, Science and Research, Infectious Diseases Society of America

# Erin Karnes

Research Associate, Engelberg Center for Health Care Reform, The Brookings Institution

## Larry Kocot

Deputy Director, Engelberg Center for Health Care Reform Visiting Fellow, Economic Studies, The Brookings Institution

## Carl N. Kraus

Vice President, Medical Affairs, Medscape/WebMD

## Katie Laessig

Deputy Director, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

### Lisa Lavange

Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

### John Lazor

Director, Division of Clinical Pharmacology 4 / Office of Clinical Pharmacology/OTS, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

### Dara Lieberman

Senior Government Relations Manager, Trust for America's Health

#### Daphne Lin

Deputy Director, Division of Biometrics IV, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food & Drug Administration

### **Ruth Lopert**

Visiting Professor, Department of Health Policy, George Washington University

#### Mark McClellan

Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, and Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution

#### Theresa Mullin

Director, Office of Planning and Informatics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

# Sumati Nambiar

Deputy Director for Safety, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

## **Anne Pariser**

Associate Director for Rare Diseases, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

### **Richard Platt**

Professor and Chair of the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute

# John Powers

Senior Medical Scientist, Science Applications International Corporation in support of the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Associate Clinical Professor of Medicine, George Washington University School of Medicine

### **Charlene Reed**

Founder and Executive Director, Foundation to Combat Antimicrobial Resistance

#### John Rex

Infection Clinical Vice President, AstraZeneca Pharmaceuticals and Adjunct Professor of Medicine, University of Texas Medical School at Houston

#### Louis Rice

Chair, Department of Medicine, Warren Alpert Medical School of Brown University and Physician-in-Chief, Rhode Island Hospital and The Miriam Hospital

### Melissa Robb

Project Director for the Sentinel Initiative, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

#### Daniel Rubin (teleconference)

Biostatistician, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

## Leonard Sacks

Medical Officer, U.S. Food and Drug Administration

### **Rachel Sherman**

Associate Director for Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

### David Shlaes

Sole Proprietor and President, Anti-Infectives Consulting

### Jean Silver-Isenstadt

Executive Director, National Physicians Alliance

#### **Brad Spellberg**

Associate Professor of Medicine, Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

#### George Talbot

Principal, Talbot Advisors LLC

#### Ram Tiwari

Associate Director for Statistical Science and Policy, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food & Drug Administration

#### Joe Toerner

Lead Medical Officer, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

#### John Tomayko

Senior Medical Director, GlaxoSmithKline

**Kathleen Uhl** (teleconference) Deputy Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Thamban Valappil** *(teleconference)* Statistician, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

## Janet Woodcock

Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration